Anti-PD1 antibody toripalimab lenvatinib and gemox chemotherapy
GBCT should not be used as an adjuvant treatment for BTC. Clinical trial identification: PRODIGE 12: EudraCT 2008-004560-39. BCAT: UMIN. 000000820.
Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma
Patients with relapsed/refractory Hodgkin lymphoma. (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients there is limited data
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint
3 févr. 2022 Conclusions A germline microRNA- based biomarker signature predicts grade 2 and higher irAEs to anti- PD1/. PDL1 therapy regardless of tumor ...
e .full
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint
resistance to anti-PD1 therapy. Results from this study demonstrated that mutations which affected the sensitivity of tumor cells to T-cell-derived
Hydroxychloroquine can impair tumor response to anti-PD1 in
22 janv. 2021 antigen-specific CD8+ T cells. This study shows that HCQ treatment can result in immunotherapy failure due to its immunosuppressive effects that ...
S ( )
A rationale for surgical debulking to improve anti-PD1 therapy
treated with anti-PD1 monoclonal antibody. Mice engrafted with two tumors also underwent a debulking surgery or a sham procedure. Tumor volume was monitored
s z ?origin=ppub
Apatinib plus camrelizumab (anti-PD1 therapy SHR-1210) for
5 mai 2020 J Immunother Cancer 2020;8:e000798. doi:10.1136/jitc-2020-000798. Open access. Apatinib plus camrelizumab (anti- PD1 therapy SHR-1210) for ...
e .full
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a
6 juin 2020 Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Y. Nakamura1* K. Namikawa2
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma
21 janv. 2020 High-dose AA treatment synergized with anti-PD1 therapy in a syngeneic lymphoma mouse model resulting in marked inhibition of tumor growth ...
Durable remissions associated with anti-CTLA-4 and anti-PD1
Background: Treatment with the checkpoint inhibitors ipilimumab (IPI) and nivolu- mab (NIVO) are associated with durable remissions in patients (pts) with
- anti pd1 therapy
- anti pd1 therapy melanoma